We are proud to announce that Milla Pharmaceuticals Inc., an A.forall company, in partnership with Acella Pharmaceuticals LLC, has successfully commercialized its Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL.

Pyridostigmine Bromide Syrup is indicated for the symptomatic treatment of myasthenia gravis, a neuromuscular disorder characterized by muscle weakness and rapid fatigue.

A.forall CEO Filip Van de Vliet emphasized the significance of this achievement, stating, “After our rebranding into A.forall, uniting our teams and businesses under one single name that embodies our joint mission of making affordable medicines available to all, this fourth U.S. launch is the next big milestone for our group in 2023, which was already a very successful year for us. A year in which we also received two so-called first cycle approvals from FDA. With all other projects in our pipeline, our team looks forward to continuing that trend and turning our mission into reality.

For the full press release, click here: LINK